Navigation Links
Berger & Montague, P.C. Reminds Viropharma Shareholders That The Deadline To Petition The Court To Act As Lead Plaintiff Is July 23, 2012
Date:7/13/2012

PHILADELPHIA, July 13, 2012 /PRNewswire/ -- The law firm of Berger & Montague, P.C. was the first law firm to file a class action against Viropharma Incorporated and Vincent J. Milano in Eastern District of Pennsylvania on May 17, 2012, Docket Number 2:12-CV-02714 on behalf of all investors who purchased shares of Viropharma ("VPHM") between December 14, 2011 and April 9, 2012.

The complaint alleges that on December 14, 2011 Viropharma issued a press release announcing the modernization of labeling for Vancocin Capsules effective through the FDA's approval of a sNDA.  The press release stated, "As a result of today's sNDA approval, Viropharma believes Vancocin meets the requirements for, and thus has, three years of exclusivity, and that generic Vancomycin capsules will not be approved during this time period."

As a result of the materially false and misleading representation about market exclusivity in the December 14, 2011 press release, the market price of Viropharma stock jumped $4.21 per share, from a closing price of $23.59 per share on December 13, 2011 to a closing price of $27.80 on December 14, 2011, on heavy volume of almost five million shares.

On April 10, 2012 before the market opening, the company filed a 8-K with the SEC attaching a press release which stated among other things that the FDA informed Viropharma that the recent supplemental new drug application (sNDA) for Vancocin approved on December 14, 2011 would not qualify for three additional years of exclusivity based on the agency's assertion that in order for an sNDA for an old antibiotic such as Vancocin to be eligible for a grant of exclusivity, it must be a significant new use or indication.  The FDA also indicated that it was approving three ANDA's for generic Vancomycin capsules.

In addition, the company received notification that the Federal Trade Commission is conducting an investigation into whether the company has engaged in unfair methods of competition with respect to Vancocin.

As a result, at the close of trading on April 10, 2012, Viropharma shares had declined $6.17 per share or 22% to close at $22.44 per share on extraordinarily high trading volume.

For more information about this case, please contact

Sherrie R. Savett, Esq.
Douglas R. Risen, Esq.
BERGER & MONTAGUE, P.C.
1622 Locust Street
Philadelphia, PA 19103
888-891-2289
info@bm.net


'/>"/>
SOURCE Berger & Montague, P.C.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Physician-Patient Alliance for Health & Safety: Monitoring the High-Acuity Patient: Does Risk Stratification Increase or Decrease Patient Safety?
2. Acella Pharmaceuticals, LLC, files Abbreviated New Drug Application (ANDA) With the U.S. Food & Drug Administration for Topical Corticosteroids Lotion
3. DePuy & Transvaginal Mesh Lawsuit Settlement Funding Leads Legal-Bay to Banner 2nd Quarter
4. Medical Diagnostic & Therapeutic Ultrasound Devices Market (2012 - 2017) - Global Trends & Competitive Analysis
5. Sanford Wittels & Heisler Files $100 Million Gender Discrimination Class Action In Southern District Of New York
6. Frost & Sullivan: European Bipolar Therapeutics Market Slows Down in the Short Term As Key Blockbuster Drugs Go Off Patent
7. Radiotherapy Devices Market By Technology, Applications & Products (2011 - 2016)
8. Clinical Chemistry Market Report & Forecast (2012 - 2015): Global Analysis
9. Law Office of Brodsky & Smith, LLC Announces Investigation of Amylin Pharmaceuticals, Inc.
10. MedAvante Honored By Ernst & Young LLP and Red Herring
11. Frost & Sullivan Recognizes Siemens Healthcares CT Imaging Solution for the Value it Offers Both Service Providers and Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2017)... Mich. , July 13, 2017  Centurion Medical Products, a ... its DisImpactor ® fecal impaction removal device for hospice patient ... ... Patient pain management and ... for Hospice can help alleviate patient pain while preventing unneeded emergency ...
(Date:7/13/2017)... ROCKVILLE, Md. , July 13, 2017  New York ... watchers of pharmaceutical markets should be aware of.  From new ... These trends are detailed in a recently completed study, ... following: 1.  Age-Driven ... years, we have been aware of the impact the growing ...
(Date:7/12/2017)... and Company (NYSE: LLY ) has entered into ... litigation in the U.S. District Court for the Eastern District ... (tadalafil) unit dose patent. This patent was previously set ... agreement, Cialis exclusivity is now expected to end at the ... patent for Cialis is valid and infringed by companies seeking ...
Breaking Medicine Technology:
(Date:7/26/2017)... ... July 26, 2017 , ... “We are dentists and we thought there ... Jose, Calif., “so we invented the MAGNETIC/ LOCK BRACKETS.” , The patent-pending MAGNETIC/ LOCK ... In doing so, it offers an effective alternative to traditional braces. As a result, ...
(Date:7/26/2017)... 92660 (PRWEB) , ... July 26, 2017 ... ... Prevention for on-premises, off and in the cloud ; today announced the availability ... scientific algorithms within a simple to use control console for Data Discovery, Classification, ...
(Date:7/26/2017)... ... July 26, 2017 , ... A global center of ... The state of the art center will provide advanced surgical care (heart ... of providing heart patients longer lives. , North American Veterinary Heart Center, the ...
(Date:7/26/2017)... ... 2017 , ... The Amnesty Rally 2017 will be held on Saturday, July ... Park Drive in Monroe (adjacent to the Louisiana Purchase Gardens & Zoo). , ... throughout Monroe. Citizens can turn in unregistered, illegally-held and imitation guns to law enforcement ...
(Date:7/26/2017)... ... July 26, 2017 , ... The number of adults ... United States, but ways to improve asthma control in the population are not well ... Practice (JACI: In Practice), an official journal of the American Academy of Allergy, Asthma ...
Breaking Medicine News(10 mins):